<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SCM</journal-id>
<journal-id journal-id-type="hwp">spscm</journal-id>
<journal-title>Scottish Medical Journal</journal-title>
<issn pub-type="ppub">0036-9330</issn>
<issn pub-type="epub">2045-6441</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0036933013482647</article-id>
<article-id pub-id-type="publisher-id">10.1177_0036933013482647</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Bilateral endogenous <italic>Serratia marcescens</italic> endophthalmitis secondary to endocarditis following cardiac surgery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lyall</surname><given-names>DAM</given-names></name>
<xref ref-type="aff" rid="aff1-0036933013482647">1</xref>
<xref ref-type="corresp" rid="corresp1-0036933013482647"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Gregory</surname><given-names>ME</given-names></name>
<xref ref-type="aff" rid="aff2-0036933013482647">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>McDonnell</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff3-0036933013482647">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>De Villiers</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff4-0036933013482647">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tejwani</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff5-0036933013482647">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0036933013482647"><label>1</label>Specialty Registrar, Tennent Institute of Ophthalmology, Gartnavel General Hospital, UK</aff>
<aff id="aff2-0036933013482647"><label>2</label>Consultant Ophthalmologist, Department of Ophthalmology, Stobhill Hospital, UK</aff>
<aff id="aff3-0036933013482647"><label>3</label>Specialty Registrar, Sir Charles Gairdner Hospital, Australia</aff>
<aff id="aff4-0036933013482647"><label>4</label>Consultant Microbiologist, Department of Microbiology, Inverclyde Royal Hospital, UK</aff>
<aff id="aff5-0036933013482647"><label>5</label>Consultant Ophthalmologist, Department of Ophthalmology, Inverclyde Royal Hospital, UK</aff>
<author-notes>
<corresp id="corresp1-0036933013482647">D Lyall, Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow G12 0YN, UK. Email: <email>douglasamlyall@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>58</volume>
<issue>2</issue>
<fpage>e1</fpage>
<lpage>e6</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The Scottish Medical Journal</copyright-holder>
</permissions>
<abstract>
<sec id="sec18-0036933013482647">
<title>Introduction</title>
<p>Endogenous endophthalmitis is a sight-threatening condition caused by microorganisms crossing the blood–ocular barrier and inducing profound intraocular inflammation.</p>
</sec>
<sec id="sec19-0036933013482647">
<title>Case report</title>
<p>A 65-year-old female experienced bilateral loss of vision after developing infective endocarditis as a complication of combined Bentall procedure and coronary artery bypass grafting. She was diagnosed with bilateral endogenous endophthalmitis secondary to <italic>Serratia marcescens.</italic> Despite aggressive treatment with intravitreal injections of antibiotics and steroids, intensive topical and systemic antibiotic therapy, there was permanent loss of sight in both eyes.</p>
</sec>
<sec id="sec20-0036933013482647">
<title>Conclusion</title>
<p>The case highlights the importance of early recognition of the symptoms and signs of endogenous endophthalmitis in any patient with systemic infection by all clinicians and the necessity of prompt ophthalmological referral if a useful level of vision is to be preserved.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Endogenous endophthalmitis</kwd>
<kwd><italic>Serratia marcescens</italic></kwd>
<kwd>intraocular inflammation</kwd>
<kwd>endocarditis</kwd>
<kwd>blood–ocular barrier</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0036933013482647" sec-type="intro"><title>Introduction</title>
<p>Endogenous endophthalmitis is a sight-threatening condition characterised by profound infective intraocular inflammation and tissue destruction that may occur in any patient with systemic infection of any underlying aetiology. Presenting signs and symptoms can be variable depending on severity of inflammation. Therefore, endogenous endophthalmitis should be considered in the differential diagnosis of any patient with systemic infection who reports new onset visual or ocular symptoms. We describe a patient who developed bilateral endogenous endophthalmitis that lead to profound visual loss. The case illustrates the importance of prompt ophthalmological assessment and demonstrates the benefits of a multidisciplinary team approach to patient care.</p>
</sec>
<sec id="sec2-0036933013482647" sec-type="cases"><title>Case presentation</title>
<p>A 65-year-old female was admitted to the Coronary Care Unit with uncontrolled atrial fibrillation and suspected endocarditis after a 3-day history of dyspnoea, lethargy and pyrexia. Fourteen days earlier she had undergone combined elective Bentall procedure and coronary artery bypass graft surgery to treat an ascending aortic aneurysm, aortic valve stenosis and narrowing of the left anterior descending and obtuse marginal arteries. Blood cultures taken on admission were positive for <italic>Serratia marcescens</italic> and systemic antibiotic therapy consisted of oral ciprofloxacin, intravenous meropenem and gentamicin.</p>
<p>On admission she reported blurring of vision followed by onset of bilateral ocular pain. Bedside examination at this stage found visual acuity to be perception of light in both eyes, bilateral swollen eyelids, conjunctival injection, chemosis, fibrinous anterior uveitis and unreactive pupils. Ocular movements were limited in all directions and intraocular pressure by digital estimation was high in both eyes.</p>
<p>In light of her systemic condition and ophthalmic clinical findings a diagnosis of bilateral endogenous endophthalmitis was made.</p>
</sec>
<sec id="sec3-0036933013482647"><title>Investigations</title>
<p>In order to identify a systemic source of her infection, and in light of her recent cardiac surgery, a transoesophageal echocardiogram was performed. This showed vegetations on the atrial side of the aortic root graft. It is thought that this was the primary focus leading to the development of endophthalmitis (<xref ref-type="fig" rid="fig1-0036933013482647">Figure 1</xref>). Orbital CT scan revealed scleral thickening and inflammatory tissue within both vitreous cavities but no intraorbital collection (<xref ref-type="fig" rid="fig2-0036933013482647">Figure 2</xref>).
<fig id="fig1-0036933013482647" position="float"><label>Figure 1.</label><caption><p>Transoesophageal echocardiogram showing a well-demarcated isodense mass on the atrial side of the aortic root graft (yellow arrow) representing infective vegetations.</p></caption><graphic xlink:href="10.1177_0036933013482647-fig1.tif"/>
</fig>
<fig id="fig2-0036933013482647" position="float"><label>Figure 2.</label><caption><p>CT of orbits. There is bilateral proptosis, scleral thickening (yellow arrow) and inflammatory tissue within both vitreous cavities (white arrow).</p></caption><graphic xlink:href="10.1177_0036933013482647-fig2.tif"/>
</fig></p>
<p>In addition to positive blood cultures for <italic>S. marcescens,</italic> both aqueous and vitreous samples from each eye were obtained for microbiological analysis in order to establish the causative infective organism in the eye. All four samples grew <italic>S. marcescens.</italic></p>
</sec>
<sec id="sec4-0036933013482647"><title>Differential diagnosis</title>
<p>The clinical symptoms and signs of endogenous endophthalmitis include ocular pain, blurred vision, photophobia, floaters, swollen eyelids, proptosis, conjunctival injection, a reduced red reflex, raised intraocular pressure, poor retinal view and hypopyon.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref></sup> Patients may not necessarily develop all these symptoms or signs but, with a relevant history, endogenous endophthalmitis must be suspected and treated promptly, as a delayed diagnosis is a poor prognostic factor for visual recovery. A variety of other ophthalmic conditions may be included in the differential diagnosis of endogenous endophthalmitis, the most significant being acute anterior uveitis, orbital cellulitis or acute angle closure glaucoma.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref></sup></p>
</sec>
<sec id="sec5-0036933013482647"><title>Treatment</title>
<p>Based on the growth-positive blood culture of <italic>S. marcescens</italic>, initial therapy consisted of intravitreal injection of ceftazidime to both eyes and 2-hourly topical ceftazidime eye drops.</p>
<p><italic>Serratia marcescens</italic> is a Gram-negative coccobacillus of the Enterobacteriaceae family that has developed resistance to β-lactam antibiotics through AmpC β-lactamases.<sup><xref ref-type="bibr" rid="bibr2-0036933013482647">2</xref></sup> A patient may respond to an initial dose of a β-lactam, such as ceftazidime, but this will also induce expression of AmpC β-lactamases genes, rendering subsequent doses ineffective. In view of this, topical ceftazidime therapy was changed to intensive ciprofloxacin eye drops after 3 days, based on culture sensitivities.</p>
<p>She also required intravenous mannitol, oral acetazolamide, topical latanoprost, apraclonidine and prednisolone eye drops in order to lower her intraocular pressure and reduce inflammation.</p>
</sec>
<sec id="sec6-0036933013482647"><title>Outcome</title>
<p>Despite initial therapy, our patient’s condition deteriorated with the development of bilateral hypopyon and deterioration of visual acuity to no perception of light in both eyes over 3 days (<xref ref-type="fig" rid="fig3-0036933013482647">Figure 3</xref>). Therefore, repeat intravitreal therapy with amikacin, based on culture sensitivities, and dexamethasone was performed on both eyes. Over several weeks treatment with topical ciprofloxacin, prednisolone and intraocular pressure lowering eye drops there was resolution of the inflammation and hypopyon and normalisation of intraocular pressure. However, her visual acuity has remained at no perception of light in both eyes and bilateral scleral perforations with uveal tissue prolapse occurring as a result of the initial inflammatory processes (<xref ref-type="fig" rid="fig4-0036933013482647">Figure 4</xref>). There is no hope of visual recovery.
<fig id="fig3-0036933013482647" position="float"><label>Figure 3.</label><caption><p>Photograph of right eye showing a fibrinous plaque in the anterior chamber (yellow arrow) with a membrane over the pupil preventing any posterior segmental view. There was no red reflex in either eye.</p></caption><graphic xlink:href="10.1177_0036933013482647-fig3.tif"/>
</fig>
<fig id="fig4-0036933013482647" position="float"><label>Figure 4.</label><caption><p>Photograph of right eye. Although the patient’s eye is comfortable, prolapsed uveal tissue (yellow arrow) can be seen with an early phthisical appearance.</p></caption><graphic xlink:href="10.1177_0036933013482647-fig4.tif"/>
</fig></p>
</sec>
<sec id="sec7-0036933013482647" sec-type="discussion"><title>Discussion</title>
<p>Endophthalmitis can be classified as either exogenous or endogenous in nature. Exogenous endophthalmitis, the more common of the two, occurs when infective agents cross the external ocular barriers into the eye, as a complication of intraocular surgery or following penetrating ocular trauma.<sup><xref ref-type="bibr" rid="bibr3-0036933013482647">3</xref><xref ref-type="bibr" rid="bibr4-0036933013482647"/>–<xref ref-type="bibr" rid="bibr5-0036933013482647">5</xref></sup></p>
<p>Endogenous endophthalmitis is an intraocular inflammation of infective aetiology caused by haematogenous spread of organisms crossing the blood–ocular barrier and invading intraocular structures. It accounts for 10% of cases of endophthalmitis and occurs bilaterally 25% of the time.<sup><xref ref-type="bibr" rid="bibr4-0036933013482647">4</xref>,<xref ref-type="bibr" rid="bibr6-0036933013482647">6</xref></sup></p>
<p>Jackson et al.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref></sup> found in a large study that the primary focus of infection is only identified in 67% of cases. Common sources include the endocardium (10%), meninges, urinary tract, hepatobiliary and wound infections.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref>,<xref ref-type="bibr" rid="bibr6-0036933013482647">6</xref></sup></p>
<p>Risk factors include diabetes, immunosuppression, autoimmune disease, intravenous drug abuse, recent surgery and indwelling catheters.<sup><xref ref-type="bibr" rid="bibr7-0036933013482647">7</xref></sup> A spectrum of bacteria or fungi are responsible with <italic>Staphylococcus aureus</italic> being the most common. <italic>Klebsiella</italic> species are the most frequent Gram-negative organism, while <italic>Serratia</italic> species are responsible for only 2–4% of all cases.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref></sup></p>
</sec>
<sec id="sec8-0036933013482647"><title>Serratia marcescens</title>
<p><italic>Serratia marcescens</italic> is a Gram-negative coccobacillus of the Enterobacteriaceae family that normally causes respiratory, urinary tract and wound infections.<sup><xref ref-type="bibr" rid="bibr8-0036933013482647">8</xref></sup> Like most Gram-negative bacilli, it has developed resistance to β-lactam antibiotics.<sup><xref ref-type="bibr" rid="bibr2-0036933013482647">2</xref>,<xref ref-type="bibr" rid="bibr9-0036933013482647">9</xref></sup> The group of enzymes responsible for <italic>S. marcescens</italic> resistance is known as AmpC β-lactamases, which are encoded in both chromosomal and plasmid genes of several Gram-negative bacilli.<sup><xref ref-type="bibr" rid="bibr2-0036933013482647">2</xref></sup> <italic>Serratia</italic> species and other members of the Enterobacteriaceae family usually have AmpC enzymes that are chromosomal and inducible by exposure to β-lactams. In vitro these organisms may appear susceptible to the third generation cephalosporins, but therapeutic use may select for derepressed mutants and resultant clinical failure. It has therefore been recommended that laboratories report all <italic>Serratia</italic> species (<italic>inter alia</italic>) as resistant to the third generation cephalosporins. This presents a management challenge, as seen with our case, as a patient may respond to an initial dose of a β-lactam, such as ceftazidime, but this will also induce expression of AmpC β-lactamases genes, rendering subsequent doses ineffective. This is why our patient’s treatment was changed from topical ceftazidime to ciprofloxacin at an early stage.</p>
<p><italic>Serratia marcescens</italic> is a rare cause of endocarditis and has been reported in patients following mitral and aortic valve surgery.<sup><xref ref-type="bibr" rid="bibr10-0036933013482647">10</xref>,<xref ref-type="bibr" rid="bibr11-0036933013482647">11</xref></sup> Prognosis is poor with a disappointing response to antibiotics attributable to the virulence of the bacteria, especially when infection is established on the suture line of the cardiotomy and valve prosthesis.<sup><xref ref-type="bibr" rid="bibr10-0036933013482647">10</xref>,<xref ref-type="bibr" rid="bibr12-0036933013482647">12</xref></sup> Risk factors for infection following cardiac surgery include operation length, suboptimal tissue perfusion and the use of indwelling catheters and cannulae. Sternotomy wounds, urinary and respiratory tracts are recognised sources of infection.<sup><xref ref-type="bibr" rid="bibr12-0036933013482647">12</xref><xref ref-type="bibr" rid="bibr13-0036933013482647"/>–<xref ref-type="bibr" rid="bibr14-0036933013482647">14</xref></sup> Post-operative endocarditis with infection of a prosthetic valve requires intensive antibiotic therapy. Although surgical intervention may be indicated, complication rates are high.<sup><xref ref-type="bibr" rid="bibr15-0036933013482647">15</xref></sup></p>
<p><italic>Serratia marcescens</italic> can cause lacrimal, orbital and ocular infections including conjunctivitis, keratitis and both exogenous and endogenous endophthalmitis.<sup><xref ref-type="bibr" rid="bibr16-0036933013482647">16</xref><xref ref-type="bibr" rid="bibr17-0036933013482647"/>–<xref ref-type="bibr" rid="bibr18-0036933013482647">18</xref></sup> Cohen et al.<sup><xref ref-type="bibr" rid="bibr17-0036933013482647">17</xref></sup> found that 5 out of 10 cases of <italic>Serratia-</italic>related endophthalmitis that were re-biopsied after appropriate intravitreal and systemic treatment still grew the organism, suggesting that <italic>Serratia</italic> can cause persistent endophthalmitis. This highlights the difficulty of dealing with the resistance mechanisms that this organism possesses.</p>
</sec>
<sec id="sec9-0036933013482647"><title>Management of endogenous endophthalmitis</title>
<sec id="sec10-0036933013482647"><title>Investigations</title>
<p>Blood cultures are the most reliable form of investigation identifying the causative organism of systemic infection in 96% of cases of endogenous endophthalmitis.<sup><xref ref-type="bibr" rid="bibr5-0036933013482647">5</xref></sup> However, in order to establish the causative pathogen in the eye, both aqueous and vitreous samples should be obtained for microbiology assessment.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref>,<xref ref-type="bibr" rid="bibr6-0036933013482647">6</xref></sup> Approximately 56–73% of vitreous samples yield a causative organism.<sup><xref ref-type="bibr" rid="bibr5-0036933013482647">5</xref>,<xref ref-type="bibr" rid="bibr19-0036933013482647">19</xref>,<xref ref-type="bibr" rid="bibr20-0036933013482647">20</xref></sup></p>
<p>Polymerase chain reaction (PCR) is another highly sensitive investigation, which gives positive results even if samples are taken after the delivery of antibiotics.<sup><xref ref-type="bibr" rid="bibr21-0036933013482647">21</xref></sup> However, its high sensitivity may lead to false positive results unless meticulous care is taken when obtaining and processing samples.<sup><xref ref-type="bibr" rid="bibr22-0036933013482647">22</xref></sup> PCR testing for bacterial pathogens in aqueous or vitreous specimens is not readily available to every unit and cannot (yet) be used as a complete substitute for formal sensitivity testing. PCR testing of such specimens could theoretically be done for the most likely pathogen but organisms not specifically probed for, could be missed. In our unit, targeted PCR testing is not readily available on site for all pathogens, albeit with a 2- to 4-day turnaround time, thus we relied on formal sensitivity testing for diagnosis.<sup><xref ref-type="bibr" rid="bibr23-0036933013482647">23</xref></sup></p>
</sec>
<sec id="sec11-0036933013482647"><title>Medical management</title>
<p>The methodology of treating endogenous endophthalmitis is similar to that of the more common exogenous endophthalmitis. Since the initial diagnosis is made clinically, antibiotic therapy is empirical and should have broad coverage. Gram-positive organisms are generally covered by vancomycin.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref></sup> For Gram-negative organisms, intravitreal ceftazidime is advocated as first line therapy, as the use of gentamicin and amikacin can be associated with retinal ischaemia and toxicity, respectively.<sup><xref ref-type="bibr" rid="bibr24-0036933013482647">24</xref><xref ref-type="bibr" rid="bibr25-0036933013482647"/>–<xref ref-type="bibr" rid="bibr26-0036933013482647">26</xref></sup> In our patient, <italic>S. marcescens</italic> had already been identified by blood culture so vancomycin would have had no therapeutic value. As the initial dose of ceftazidime had been ineffective, amikacin was given as a second line therapy guided by culture sensitivity. The benefit of systemic antibiotics in endophthalmitis is limited due to poor ocular penetration but by definition endogenous endophthalmitis will have a primary focus of infection requiring systemic treatment. Topical therapy is generally given although the evidence of therapeutic value is limited as adequate ocular penetration may not be achieved.<sup><xref ref-type="bibr" rid="bibr27-0036933013482647">27</xref></sup></p>
<p><italic>Serratia marcescens</italic> is a multi-drug-resistant organism but review of reported cases of endogenous endophthalmitis secondary to it shows aminoglycosides to be effective as a first line therapy. Even with culture-guided treatment, persisting infection is common.<sup><xref ref-type="bibr" rid="bibr28-0036933013482647">28</xref></sup> As intravitreal aminoglycosides are associated with complications, intravitreal ceftazidime (a third generation cephalosporin) is a reasonable first line therapy as it has been shown to be effective in several reported cases.<sup><xref ref-type="bibr" rid="bibr17-0036933013482647">17</xref>,<xref ref-type="bibr" rid="bibr28-0036933013482647">28</xref></sup></p>
<p>Intravitreal and systemic steroids remain a contentious issue in the treatment of endogenous endophthalmitis. The rationale behind this therapy is to diminish the intraocular destruction that occurs secondary to host inflammatory responses.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref></sup> Systemic steroids were given for a short time to our patient to reduce her significant orbital and ocular inflammation. However, in cases of uncontrolled sepsis, systemic steroids are contraindicated.</p>
</sec>
<sec id="sec12-0036933013482647"><title>Surgical management</title>
<p>The Endophthalmitis Vitrectomy Study has shown that patients with exogenous endophthalmitis benefit from vitrectomy when their visual acuity is only light perception or worse.<sup><xref ref-type="bibr" rid="bibr29-0036933013482647">29</xref></sup> However, no evidence exists advocating the benefit of vitrectomy for endogenous endophthalmitis. In view of a guarded prognosis for this treatment and high anaesthetic risk in our acutely unwell patient who had recently undergone major surgery, vitrectomy was not deemed appropriate.</p>
</sec>
</sec>
<sec id="sec13-0036933013482647"><title>Prognosis and outcomes</title>
<p>Endogenous endophthalmitis carries a poor prognosis. Despite advances in treatment, there has been little improvement in overall outcomes with less than half of patients achieving a visual acuity better than 6/60 and approximately a quarter requiring removal of the eye.<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref>,<xref ref-type="bibr" rid="bibr3-0036933013482647">3</xref>,<xref ref-type="bibr" rid="bibr7-0036933013482647">7</xref>,<xref ref-type="bibr" rid="bibr20-0036933013482647">20</xref></sup> This number increases to 50% when <italic>Serratia</italic> species are the causative organism.<sup><xref ref-type="bibr" rid="bibr17-0036933013482647">17</xref>,<xref ref-type="bibr" rid="bibr28-0036933013482647">28</xref></sup> Poor prognostic factors include a delay in diagnosis, poor visual acuity at diagnosis and virulence (Gram-negative organisms in particular).<sup><xref ref-type="bibr" rid="bibr1-0036933013482647">1</xref>,<xref ref-type="bibr" rid="bibr3-0036933013482647">3</xref>,<xref ref-type="bibr" rid="bibr7-0036933013482647">7</xref></sup></p>
</sec>
<sec id="sec14-0036933013482647" sec-type="conclusions"><title>Conclusion</title>
<p>Endogenous endophthalmitis is a sight-threatening ophthalmic emergency that even with timely treatment carries a poor visual prognosis. Prompt treatment is essential if a useful level of vision is to be preserved. Therefore, endogenous endophthalmitis should always be considered in patients with systemic infection that report some form of eye symptoms and urgent referral for ophthalmic assessment is recommended.</p>
</sec>
<sec id="sec15-0036933013482647"><title>Learning points</title>
<p>
<list id="list1-0036933013482647" list-type="bullet">
<list-item><p>Endogenous endophthalmitis is a sight-threatening ophthalmic emergency that carries a poor visual prognosis even with timely treatment.</p></list-item>
<list-item><p>All clinicians should be aware of the symptoms and signs of endogenous endophthalmitis.</p></list-item>
<list-item><p>Endogenous endophthalmitis should always be considered in patients with systemic infection that report some form of eye symptoms.</p></list-item>
<list-item><p>Prompt treatment is essential if a useful level of vision is to be preserved and urgent referral for an ophthalmic assessment is recommended.</p></list-item>
<list-item><p><italic>Serratia marcescens</italic> poses further treatment challenges and early consultation with a microbiologist is recommended to guide antimicrobial therapy.</p></list-item>
</list></p>
</sec>
</body>
<back>
<sec id="sec16-0036933013482647"><title>Declaration of conflicting interests</title>
<p>None declared.</p>
</sec>
<sec id="sec17-0036933013482647"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0036933013482647"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>TL</given-names></name><name><surname>Eykyn</surname><given-names>SJ</given-names></name><name><surname>Graham</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>Endogenous bacterial endophthalmitis: A 17-year prospective series and review of 267 reported cases</article-title>. <source>Surv Ophthalmol</source> <year>2003</year>; <volume>48</volume>: <fpage>403</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr2-0036933013482647"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacoby</surname><given-names>GA</given-names></name><name><surname>Munoz-Price</surname><given-names>LS</given-names></name></person-group>. <article-title>The new beta-lactamases</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>352</volume>: <fpage>380</fpage>–<lpage>391</lpage>.</citation></ref>
<ref id="bibr3-0036933013482647"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koul</surname><given-names>S</given-names></name><name><surname>Philipson</surname><given-names>A</given-names></name><name><surname>Philipson</surname><given-names>BT</given-names></name></person-group>. <article-title>Incidence of endophthalmitis in Sweden</article-title>. <source>Acta Ophthalmol (Copenh)</source> <year>1989</year>; <volume>67</volume>: <fpage>499</fpage>–<lpage>503</lpage>.</citation></ref>
<ref id="bibr4-0036933013482647"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shrader</surname><given-names>SK</given-names></name><name><surname>Band</surname><given-names>JD</given-names></name><name><surname>Lauter</surname><given-names>CB</given-names></name><etal/></person-group>. <article-title>The clinical spectrum of endophthalmitis: Incidence, predisposing factors and features influencing outcome</article-title>. <source>J Infect Dis</source> <year>1990</year>; <volume>162</volume>: <fpage>115</fpage>–<lpage>120</lpage>.</citation></ref>
<ref id="bibr5-0036933013482647"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>AA</given-names></name><name><surname>Johnson</surname><given-names>RP</given-names></name><name><surname>Liles</surname><given-names>WC</given-names></name><etal/></person-group>. <article-title>Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study</article-title>. <source>Ophthalmology</source> <year>1994</year>; <volume>101</volume>(<issue>5</issue>): <fpage>832</fpage>–<lpage>886</lpage>.</citation></ref>
<ref id="bibr6-0036933013482647"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenwald</surname><given-names>MJ</given-names></name><name><surname>Wohl</surname><given-names>LG</given-names></name><name><surname>Sell</surname><given-names>CH</given-names></name></person-group>. <article-title>Metastatic bacterial endophthalmitis: A contemporary reappraisal</article-title>. <source>Surv Ophthalmol</source> <year>1986</year>; <volume>31</volume>(<issue>2</issue>): <fpage>81</fpage>–<lpage>101</lpage>.</citation></ref>
<ref id="bibr7-0036933013482647"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chee</surname><given-names>SP</given-names></name><name><surname>Jap</surname><given-names>A</given-names></name></person-group>. <article-title>Endogenous endophthalmitis</article-title>. <source>Curr Opin Ophthalmol</source> <year>2001</year>; <volume>12</volume>(<issue>6</issue>): <fpage>464</fpage>–<lpage>470</lpage>.</citation></ref>
<ref id="bibr8-0036933013482647"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkowske</surname><given-names>CJ</given-names></name><name><surname>Washington</surname><given-names>JA</given-names></name><name><surname>Martin</surname><given-names>WJ</given-names></name><etal/></person-group>. <article-title>Serratia marcescens: Biochemical characteristics, antibiotic susceptibility patterns and clinical significance</article-title>. <source>JAMA</source> <year>1970</year>; <volume>214</volume>: <fpage>2157</fpage>–<lpage>2162</lpage>.</citation></ref>
<ref id="bibr9-0036933013482647"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RN</given-names></name></person-group>. <article-title>Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: The Amp C enzymes</article-title>. <source>Diagn Microbiol Infect Dis</source> <year>1998</year>; <volume>31</volume>: <fpage>461</fpage>–<lpage>466</lpage>.</citation></ref>
<ref id="bibr10-0036933013482647"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suri</surname><given-names>RK</given-names></name><name><surname>Selby</surname><given-names>DA</given-names></name><name><surname>Hawks</surname><given-names>GH</given-names></name><etal/></person-group>. <article-title>Serratia marcescens endocarditis. A report of a case involving Cross-Jones mitral valve prosthesis, with a review of the literature</article-title>. <source>Can Med Assoc J</source> <year>1971</year>; <volume>104</volume>: <fpage>1013</fpage>–<lpage>1014</lpage>.</citation></ref>
<ref id="bibr11-0036933013482647"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>R</given-names></name><name><surname>Mills</surname><given-names>J</given-names></name></person-group>. <article-title>Serratia endocarditis: A follow-up report</article-title>. <source>Arch Intern Med</source> <year>1980</year>; <volume>140</volume>: <fpage>19</fpage>–<lpage>202</lpage>.</citation></ref>
<ref id="bibr12-0036933013482647"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orita</surname><given-names>H</given-names></name><name><surname>Shimanuki</surname><given-names>T</given-names></name><name><surname>Fukasawa</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A clinical study of postoperative infections following open-heart surgery: occurrence and micro-biological findings in 782 cases</article-title>. <source>Surg Today</source> <year>1992</year>; <volume>22</volume>: <fpage>207</fpage>–<lpage>212</lpage>.</citation></ref>
<ref id="bibr13-0036933013482647"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dismukes</surname><given-names>WE</given-names></name><name><surname>Karchmer</surname><given-names>AW</given-names></name><name><surname>Buckley</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Prosthetic valve endocarditis. Analysis of 38 cases</article-title>. <source>Circulation</source> <year>1973</year>; <volume>48</volume>: <fpage>365</fpage>–<lpage>377</lpage>.</citation></ref>
<ref id="bibr14-0036933013482647"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lockey</surname><given-names>E</given-names></name><name><surname>Gonzalez-Lavin</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Bacteremia after open-heart surgery</article-title>. <source>Thorax</source> <year>1973</year>; <volume>28</volume>: <fpage>183</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr15-0036933013482647"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jubair</surname><given-names>KA</given-names></name><name><surname>Al Fagih</surname><given-names>MR</given-names></name><name><surname>Ashmeg</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Cardiac operations during active endocarditis</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>1992</year>; <volume>104</volume>: <fpage>487</fpage>–<lpage>490</lpage>.</citation></ref>
<ref id="bibr16-0036933013482647"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atlee</surname><given-names>WE</given-names></name><name><surname>Burns</surname><given-names>RP</given-names></name><name><surname>Oden</surname><given-names>M</given-names></name></person-group>. <article-title>Serratia marcescens keratoconjunctivitis</article-title>. <source>Am J Ophthalmol</source> <year>1970</year>; <volume>70</volume>: <fpage>31</fpage>–<lpage>33</lpage>.</citation></ref>
<ref id="bibr17-0036933013482647"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>SM</given-names></name><name><surname>Flynn</surname><given-names>HW</given-names><suffix>Jr</suffix></name><name><surname>Miller</surname><given-names>D</given-names></name></person-group>. <article-title>Endophthalmitis caused by Serratia marcescens</article-title>. <source>Ophthalmic Surg Lasers</source> <year>1997</year>; <volume>28</volume>: <fpage>195</fpage>–<lpage>200</lpage>.</citation></ref>
<ref id="bibr18-0036933013482647"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donnenfeld</surname><given-names>ED</given-names></name><name><surname>Schrier</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>HD</given-names></name><etal/></person-group>. <article-title>Infectious keratitis with corneal perforation associated with corneal hydrops and contact lens wear in keratoconus</article-title>. <source>Br J Ophthalmol</source> <year>1996</year>; <volume>80</volume>(<issue>5</issue>): <fpage>409</fpage>–<lpage>412</lpage>.</citation></ref>
<ref id="bibr19-0036933013482647"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname><given-names>MI</given-names></name><name><surname>Chua</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name><etal/></person-group>. <article-title>Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center</article-title>. <source>Medicine (Baltimore)</source> <year>2003</year>; <volume>82</volume>: <fpage>97</fpage>–<lpage>105</lpage>.</citation></ref>
<ref id="bibr20-0036933013482647"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keswani</surname><given-names>T</given-names></name><name><surname>Ahuja</surname><given-names>V</given-names></name><name><surname>Changulani</surname><given-names>M</given-names></name></person-group>. <article-title>Evaluation of outcome of various treatment methods for endogenous endophthalmitis</article-title>. <source>Indian J Med Sci</source> <year>2006</year>; <volume>60</volume>: <fpage>454</fpage>–<lpage>460</lpage>.</citation></ref>
<ref id="bibr21-0036933013482647"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okhravi</surname><given-names>N</given-names></name><name><surname>Adamson</surname><given-names>P</given-names></name><name><surname>Carroll</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>PCR-based evidence of bacterial involvement in eyes with suspected intraocular infection</article-title>. <source>Invest Ophthalmol Vis Sci</source> <year>2000</year>; <volume>41</volume>: <fpage>3474</fpage>–<lpage>3479</lpage>.</citation></ref>
<ref id="bibr22-0036933013482647"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lohmann</surname><given-names>CP</given-names></name><name><surname>Linde</surname><given-names>HJ</given-names></name><name><surname>Reischi</surname><given-names>U</given-names></name></person-group>. <article-title>Improved detection of microorganisms by polymerase chain reaction in delayed endophthalmitis after cataract surgery</article-title>. <source>Ophthalmology</source> <year>2000</year>; <volume>107</volume>: <fpage>1047</fpage>–<lpage>1051</lpage>.</citation></ref>
<ref id="bibr23-0036933013482647"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livermore</surname><given-names>DM</given-names></name><name><surname>Brown</surname><given-names>DF</given-names></name></person-group>. <article-title>Detection of beta-lactamase-mediated resistance</article-title>. <source>J Antimicrob Chemother</source> <year>2001</year>; <volume>48</volume>: <fpage>59</fpage>–<lpage>64</lpage>.</citation></ref>
<ref id="bibr24-0036933013482647"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname><given-names>PA</given-names></name><name><surname>Conway</surname><given-names>BP</given-names></name></person-group>. <article-title>Aminoglycoside toxicity – a survey of retinal specialists. Implications for ocular use</article-title>. <source>Arch Ophthalmol</source> <year>1991</year>; <volume>109</volume>: <fpage>946</fpage>–<lpage>950</lpage>.</citation></ref>
<ref id="bibr25-0036933013482647"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname><given-names>PA</given-names></name><name><surname>Lim</surname><given-names>JI</given-names></name></person-group>. <article-title>Aminoglycoside toxicity in the treatment of endophthalmitis. The Aminoglycoside Toxicity Study Group</article-title>. <source>Arch Ophthalmol</source> <year>1994</year>; <volume>112</volume>: <fpage>48</fpage>–<lpage>53</lpage>.</citation></ref>
<ref id="bibr26-0036933013482647"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doft</surname><given-names>BH</given-names></name><name><surname>Barza</surname><given-names>M</given-names></name></person-group>. <article-title>Ceftazidime or amikacin: Choice of intravitreal antimicrobials in the treatment of postoperative endophthalmitis</article-title>. <source>Arch Ophthalmol</source> <year>1994</year>; <volume>112</volume>: <fpage>17</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr27-0036933013482647"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Hata</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration</article-title>. <source>Eur J Ophthalmol</source> <year>2007</year>; <volume>17</volume>: <fpage>372</fpage>–<lpage>372</lpage>.</citation></ref>
<ref id="bibr28-0036933013482647"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Equi</surname><given-names>RA</given-names></name><name><surname>Green</surname><given-names>WR</given-names></name></person-group>. <article-title>Endogenous Serratia marcescens endophthalmitis with dark hypopyon: Case report and review</article-title>. <source>Surv Ophthalmol</source> <year>2001</year>; <volume>46</volume>: <fpage>259</fpage>–<lpage>259</lpage>.</citation></ref>
<ref id="bibr29-0036933013482647"><label>29</label><citation citation-type="journal"><collab>The Endophthalmitis Vitrectomy Study Group</collab>. <article-title>Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis</article-title>. <source>Arch Ophthalmol</source> <year>1995</year>; <volume>113</volume>: <fpage>1479</fpage>–<lpage>1479</lpage>.</citation></ref>
</ref-list>
</back>
</article>